Company intelligence / Profile preview

Caraway Therapeutics

Cambridge, Massachusetts, United Statescarawayhome.com ↗

Ownership: Private
Development stage: Commercial

Overview

Caraway developed a pipeline of novel small-molecule therapeutics targeting genetically defined neurodegenerative and rare diseases by modulating cellular recycling processes such as autophagy and lysosomal function. Its lead assets targeted the TRPML1 ion channel for Parkinson’s disease and other indications. The company was acquired by Merck in November 2023 for up to $610 million, with all programs at preclinical or early clinical stages at the time of acquisition.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

TMEM175 program (WCNDD)

Preclinical

Partnerships

None disclosed beyond investors; post-acquisition R&D collaboration is internal within Merck.

Beyond the preview

Go deeper on Caraway Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caraway Therapeutics.

Explore the full profile